In the months leading up to a presidential election, when there is a chance that the White House may change occupants after November, administrations often push their agendas through federal actions, such as regulations and guidance, coming out of the federal departments.
So, while this election year we are not expecting Congress to get much done in terms of actual legislation, we can expect the Biden Administration to ramp up its efforts at pushing things through at the regulatory level.
A good example of this is the proposed rule published late last week that would, in essence, make marijuana legal for medicinal use across the country. The rule, coming out of the Drug Enforcement Administration (DEA) under the Department of Justice (DOJ), proposes that marijuana be changed to a Schedule III substance under the Controlled Substances Act.
Marijuana is currently categorized as a Schedule I substance, defined as a substance for which there is a high potential for abuse, no current medical use, and a lack of accepted safety for use, even under medical supervision.
Last week’s DEA proposed rule follows a determination from the Department of Health and Human Services (HHS) last summer that marijuana in fact does have accepted medical uses, and is less dangerous than other Schedule I drugs, which include heroin and LSD.
This move by the Administration probably triggers more questions than answers, at least with respect to its regulatory challenges. Nearly 40 states have already passed laws that legalize medical use of marijuana, though there is little in the way of state rules on prescriptions, recordkeeping, and other administrative and safety guardrails.
Although the rule would reclassify marijuana, it would still be a controlled substance, which means that federal prosecution is still a risk to anyone who traffics in the drugs or “prescribes” the drugs without the appropriate approvals and processes.
Perhaps just as important as what this proposed rule would do is what the rule would definitely not do. For instance, the proposed rule would not federally legalize marijuana to be grown and sold for recreational use. A total of 24 states allow the sale of recreational cannabis.
As an example of this, the newly proposed rule, if finalized, would not get anyone out of jail who were put there solely for growing or selling marijuana.
Relatedly, the rule would not give the cannabis industry access to credit-card and payment systems.
It is also very unclear what this means for the U.S. drug and healthcare industry at large, as you can well imagine. Could gummies bought at the neighborhood cannabis store now be covered by insurers and bought with your HSAs or FSA?
We are basically at the beginning of what may be a long rulemaking process before the rescheduling actually takes place. However, how long that will take is another question. As you may know, some regulatory changes that have popular support can move quickly from proposed rule to final rule within a year. Other rules can take years. However, we can expect that the Biden Administration will move on this rule quickly.
This may be just the latest in a number of actions that will be taken up this election year by the Biden Administration.
We’ll keep our eyes on it.
I receive a lot of newsletters every morning to help me stay abreast of what is happening in the healthcare industry. A troubling recent trend
In the CY 2026 OPPS/ASC Final Rule, the Centers for Medicare & Medicaid Services (CMS) formally finalized the removal of the Screening for Social Drivers
Please log in to your account to comment on this article.
Accurately determining the principal diagnosis is critical for compliant billing, appropriate reimbursement, and valid quality reporting — yet it remains one of the most subjective and error-prone areas in inpatient coding. In this expert-led session, Cheryl Ericson, RN, MS, CCDS, CDIP, demystifies the complexities of principal diagnosis assignment, bridging the gap between coding rules and clinical reality. Learn how to strengthen your organization’s coding accuracy, reduce denials, and ensure your documentation supports true medical necessity.
Denials continue to delay reimbursement, increase administrative burden, and threaten financial stability across healthcare organizations. This essential webcast tackles the root causes—rising payer scrutiny, fragmented workflows, inconsistent documentation, and underused analytics—and offers proven, data-driven strategies to prevent and overturn denials. Attendees will gain practical tools to strengthen documentation and coding accuracy, engage clinicians effectively, and leverage predictive analytics and AI to identify risks before they impact revenue. Through real-world case examples and actionable guidance, this session empowers coding, CDI, and revenue cycle professionals to shift from reactive appeals to proactive denial prevention and revenue protection.
Sepsis remains one of the most frequently denied and contested diagnoses, creating costly revenue loss and compliance risks. In this webcast, Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, provides practical, real-world strategies to align documentation with coding guidelines, reconcile Sepsis-2 and Sepsis-3 definitions, and apply compliant queries. You’ll learn how to identify and address documentation gaps, strengthen provider engagement, and defend diagnoses against payer scrutiny—equipping you to protect reimbursement, improve SOI/ROM capture, and reduce audit vulnerability in this high-risk area.
Only ICD10monitor delivers what you need: updates on must-know changes associated with the FY26 IPPS, including new ICD-10-CM/PCS codes, CCs/MCCs, and MS-DRGs, plus insights, analysis and answers to your questions from two of the country’s most respected subject matter experts.
Get clear, practical answers to Medicare’s most confusing regulations. Join Dr. Ronald Hirsch as he breaks down real-world compliance challenges and shares guidance your team can apply right away.
Federal auditors are zeroing in on Inpatient Rehabilitation Facility (IRF) and hospital rehab unit services, with OIG and CERT audits leading to millions in penalties—often due to documentation and administrative errors, not quality of care. Join compliance expert Michael Calahan, PA, MBA, to learn the five clinical “pillars” of IRF-PPS admissions, key documentation requirements, and real-life case lessons to help protect your revenue.
During this essential RACmonitor webcast Michael Calahan, PA, MBA Certified Compliance Officer, will clarify the rules, dispel common misconceptions, and equip you with practical strategies to code, document, and bill high-risk split/shared, incident-to & critical care E/M services with confidence. Don’t let audit risks or revenue losses catch your organization off guard — learn exactly what federal auditors are looking for and how to ensure your documentation and reporting stand up to scrutiny.
Learn how to navigate the proposed elimination of the Inpatient-Only list. Gain strategies to assess admission status, avoid denials, protect compliance, and address impacts across Medicare and non-Medicare payors. Essential insights for hospitals.
Happy National Doctor’s Day! Learn how to get a complimentary webcast on ‘Decoding Social Admissions’ as a token of our heartfelt appreciation! Click here to learn more →
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 1 with code CYBER25
CYBER WEEK IS HERE! Don’t miss your chance to get 20% off now until Dec. 2 with code CYBER24
